Pfizer, Moderna achieves 90% efficiency against Omicron: CDC | Coronavirus pandemic News

Three U.S. studies provide further evidence that the third dose of COVID vaccine is highly effective against Omicron.

Pfizer-BioNTech and Moderna vaccine booster shots have been shown to be very effective in prevention. Omikron-related hospitalizations, according to three new studies conducted by the U.S. Centers for Disease Control and Prevention.

Booster doses were 90 percent effective in keeping people out of the hospital after being infected with the Omicron variant.

Doses were 82 percent effective in preventing emergency and urgent care visits, the data show.

“It really shows the importance of getting a booster dose,” Emma Accorsi of the CDC, one of the authors of the study, said Friday.

“Americans should get boosters if at least five months have passed since they completed the Pfizer or Moderna series, but the millions they are entitled to have not gotten them.”

The investigation was the first major U.S. investigation into vaccine protection against Omicron, health officials said.

Previous research

The articles echo previous research, including studies Available vaccines in Germany, South Africa and the United Kingdom indicate that vaccines are more effective than previous versions of coronavirus, but also that booster doses boost anti-virus antibodies to increase the chances of preventing a symptomatic infection.

The first study looked at hospitalizations in 10 states and visits to emergency and emergency care centers from August to this month.

The effectiveness of the vaccine was best in preventing PFizer or Moderna vaccine after three doses of COVID-19-related emergency department and urgent care visits.

Protection fell from 94 percent in the Delta wave to 82 percent in the Omicron wave.

Protecting only two doses was less, especially if six months had elapsed since the second dose.

Officials stressed the goal is to prevent not only infections but also serious illnesses.

The second study focused on COVID-19 cases and death rates in 25 states from early April to late December.

The people who were promoted had the greatest protection against coronavirus infection, both during the Delta era and when Omicron took over.

These two articles were published online by the Centers for Disease Control and Prevention.

Third study

The American Medical Association published a third study, also conducted by CDC researchers.

From Dec. 10 to Jan. 1, it tested people who tested positive for COVID-19 at more than 4,600 U.S. test sites.

Three-thirds of the Pfizer and Moderna vaccines were about 67 percent effective against Omicron-related symptomatic disease compared to unvaccinated people.

The two doses, however, did not provide much protection against Omicron when measured within a few months of the end of the original series, the researchers found.

“If you’re eligible for a booster and you haven’t got it, you’re not up to date and you need to get your booster,” CDC Director Dr. Rochelle Walensky said at a White House conference.